Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J2A-MC-GZPO: Orforglipron in Obesity or Overweight With and Without Type 2 Diabetes
2025-521098-14-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of orforglipron in obesity, Overweight and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants Allocated to Each Study, Percent Change from Baseline in Body Weight and 1 more. Planned start Jul 2025; status: authorised.
02
Drugs
orforglipron
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2025-521098-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521098-14-00.